A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

StatusActive, Not Recruiting
PhasePhase 3
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 183 → 180 locations
  2. Trial sites reduced: 188 → 183 locations
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 2 of 32 entries
  3. Trial sites expanded: 183 → 188 locations
    • Enrollment target: 1044 to 1078
    v9
  4. Enrollment closed, study ongoing
    • Enrollment target: estimated 999 to confirmed 1044
    • Study sites: 181 to 183
    v8
  5. Study sites revised (181)v7
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 183 to 181v6
  2. Study sites: 184 to 183v5
  3. Study sites revised (184)v4
  1. Recruitment opened
    • Trial sites expanded: 0 → 184 locations
    • Start date changed from estimate of Feb 12, 2026 to Feb 24, 2026
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood. The study medicine is given by a shot under the skin in the belly area. The participants will be trained to do this at home once every week. About 660 out of 1000 adults will also receive the study medicine and about 330 out of 1000 adults will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help us assess if the study medicine is safe and effective. People will take part in this study for about 21 months. During this time, they will have about 14 study visits at the site and 5 over the phone.
Trial Details
NCT Number NCT07400653
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes
Related terms Body Weight, Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases, Nutrition Disorders, Nutritional and Metabolic Diseases, Obesity, Overnutrition, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms
Enrollment 1,078 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov